Product menu

Image of woman with a shingles rash on her forehead

Your patients ≥50 years old are at risk for shingles, even if they have a healthy lifestyle1

SHINGRIX is not indicated for the treatment of HZ or its complications, such as pain.

Age-related decline in immunity was shown to be the dominant driver of shingles1

Incidence rate (%) of shingles2*

a chart of incidence rate of shingles in percentage
a chart of incidence rate of shingles in percentage

Adapted from Tanuseputro, et al.2

Do your patients 50 years and older know they are at risk?

≥90% of Canadians have had varicella and are at risk for shingles3

It has been estimated that 1 in 3 Canadians will develop shingles at some point in their lives, increasing to almost 50% by age 85.4

Complications of shingles, including PHN (postherpetic neuralgia), increase dramatically with age.1,5

Approximately 80%−85% of PHN occurs in shingles patients aged ≥50 years.1

an image of seniors sitting down on chairs
an image of seniors sitting down on chairs

SHINGRIX is not indicated for the treatment of HZ or its complications, such as PHN.

* Rates of zoster cases requiring healthcare use in Ontario (N=13.2 million); April 1992 to March 2010 (fiscal year 1992−2009).2

Graph icon

Efficacy data for SHINGRIX4

Vaccine efficacy profile was studied in subjects ≥50 years old (ZOE-50) and subjects ≥70 years old (ZOE-70).4

Learn more
Patient icon

Start the conversation about shingles risk with your patients

Nearly everyone ≥50 years old should be protected against shingles.6

Learn more
Virus icon

Could immunocompromised patients aged ≥18 years be at risk of shingles?

Learn about different immunocompromised risk factors for shingles.7

Learn more

References:

  1. Harpaz R, et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1–30.
  2. Tanuseputro P, et al. Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine 2011;29(47):8580–8584.
  3. National Advisory Committee on Immunization (NACI). Statement on the recommended use of herpes zoster vaccine. Can Commun Dis Rep 2010;36(ACS-1):1–19.
  4. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.
  5. Centers for Disease Control and Prevention. Shingles: Clinical Overview. Available at: https://www.cdc.gov/shingles/hcp/clinical-overview.html. Accessed June 5, 2017.
  6. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed November 30, 2022.
  7. Marra F, et al. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis 2020;7(1):ofaa005.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK Group of companies or its licensor.

10572 | 05/24